口服氧硼烷 MRX-5 对小鼠肺脓肿分枝杆菌具有疗效。

IF 4.1 2区医学 Q2 MICROBIOLOGY

Antimicrobial Agents and Chemotherapy Pub Date : 2024-11-06 Epub Date: 2024-10-03 DOI:10.1128/aac.01351-24

Binayak Rimal, Ruth A Howe, Chandra M Panthi, Wen Wang, Gyanu Lamichhane

{"title":"口服氧硼烷 MRX-5 对小鼠肺脓肿分枝杆菌具有疗效。","authors":"Binayak Rimal, Ruth A Howe, Chandra M Panthi, Wen Wang, Gyanu Lamichhane","doi":"10.1128/aac.01351-24","DOIUrl":null,"url":null,"abstract":"Mycobacterium abscessus (Mab) is an opportunistic pathogen common in patients with lung comorbidities and immunosuppression. There are no FDA-approved treatments, and current treatment has a failure rate exceeding 50%. The intravenous oxaborole MRX-6038 is active against Mab. This study evaluated MRX-5, the oral prodrug, against five Mab isolates in a mouse lung infection model. MRX-5 showed dose-dependent efficacy, with 15 and 45 mg/kg doses comparable to the standard of care, supporting progression to clinical trial.","PeriodicalId":8152,"journal":{"name":"Antimicrobial Agents and Chemotherapy","volume":" ","pages":"e0135124"},"PeriodicalIF":4.1000,"publicationDate":"2024-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11539245/pdf/","citationCount":"0","resultStr":"{\"title\":\"Oral oxaborole MRX-5 exhibits efficacy against pulmonary Mycobacterium abscessus in mouse.\",\"authors\":\"Binayak Rimal, Ruth A Howe, Chandra M Panthi, Wen Wang, Gyanu Lamichhane\",\"doi\":\"10.1128/aac.01351-24\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Mycobacterium abscessus (Mab) is an opportunistic pathogen common in patients with lung comorbidities and immunosuppression. There are no FDA-approved treatments, and current treatment has a failure rate exceeding 50%. The intravenous oxaborole MRX-6038 is active against Mab. This study evaluated MRX-5, the oral prodrug, against five Mab isolates in a mouse lung infection model. MRX-5 showed dose-dependent efficacy, with 15 and 45 mg/kg doses comparable to the standard of care, supporting progression to clinical trial.\",\"PeriodicalId\":8152,\"journal\":{\"name\":\"Antimicrobial Agents and Chemotherapy\",\"volume\":\" \",\"pages\":\"e0135124\"},\"PeriodicalIF\":4.1000,\"publicationDate\":\"2024-11-06\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11539245/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Antimicrobial Agents and Chemotherapy\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1128/aac.01351-24\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/10/3 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q2\",\"JCRName\":\"MICROBIOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Antimicrobial Agents and Chemotherapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1128/aac.01351-24","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/10/3 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"MICROBIOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

脓肿分枝杆菌（Mab）是一种机会性病原体，常见于肺部合并症和免疫抑制患者。目前还没有获得美国食品及药物管理局批准的治疗方法，现有治疗的失败率超过 50%。静脉注射的氧硼烷 MRX-6038 对马布病有活性。这项研究评估了口服原药 MRX-5 在小鼠肺部感染模型中对五种马巴病毒分离物的疗效。MRX-5显示出剂量依赖性疗效，15和45毫克/千克的剂量与标准治疗相当，支持将其推向临床试验。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Oral oxaborole MRX-5 exhibits efficacy against pulmonary Mycobacterium abscessus in mouse.

Mycobacterium abscessus (Mab) is an opportunistic pathogen common in patients with lung comorbidities and immunosuppression. There are no FDA-approved treatments, and current treatment has a failure rate exceeding 50%. The intravenous oxaborole MRX-6038 is active against Mab. This study evaluated MRX-5, the oral prodrug, against five Mab isolates in a mouse lung infection model. MRX-5 showed dose-dependent efficacy, with 15 and 45 mg/kg doses comparable to the standard of care, supporting progression to clinical trial.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Antimicrobial Agents and Chemotherapy 医学-微生物学

CiteScore

10.00

自引率

8.20%

发文量

762

审稿时长

3 months

期刊介绍： Antimicrobial Agents and Chemotherapy (AAC) features interdisciplinary studies that build our understanding of the underlying mechanisms and therapeutic applications of antimicrobial and antiparasitic agents and chemotherapy.